


Allele-selective editing of mHTT utilizing AAV5delivered Life Edit® CRISPR System (LETI-101) results in meaningful reduction of mHTT protein



Logan Brown Ph.D., Nancy Cheng Ph.D., Alexandra Crawley Ph.D., Helen Mao Ph.D., Jamie Moy Ph.D., Kathryn Woodburn Ph.D.



#### **Disclaimer & Disclosures**



The information presented in this, and all sessions presented at the HSG 2023 Annual Meeting is for informational purposes only.

Relevant disclosures for this presentation, given by Logan Brown, Ph.D. include:

• An employee of Life Edit Therapeutics (an ElevateBio company)




111.1

life edit

an elevatebia company

### Life Edit Gene Editing Technology


Life Edit's Collections of Proprietary RNA guided Nucleases Enable Flexible Targeting of Disease-Linked Genes



• Life Edit Genes (LEGs) have diverse PAM recognition sequences enabling broad genome targeting

• Life Edit nucleases are compact, enabling efficient delivery with a single AAV vector

### LETI-101 Allele Selective Strategy for Huntington's Disease




• LETI-101 is selective for mHTT allele based on the PAM generated by SNP rs362331 in exon 50




• LETI-101 is a one-time treatment that permanently modifies mHTT DNA for lasting therapeutic effect

### **LETI-101 Allele Selective Editing in HD Patient Fibroblasts**




- Guide1 LETI-101 guide
- Guide2 Control targeting mHTT without PAM
- Guide3 Control targeting mouse ROSA26 gene
- LEG-B Control; nuclease without guide



Data represent mean ± SE


- mRNA/RNA transfection
- Protein quantification by capillary electrophoresis
- Subtext denotes CAG repeat length of each allele
- LETI-101 composition 'LEG-B-Guide1' selectively edits the mHTT allele only in the presence of the PAM-forming 'T' SNP rs362331
- life edit<sup>®</sup> an elevatebia<sup>®</sup> company
- LETI-101 composition 'LEG-B-Guide1' selectively reduces mutant HTT protein, but does not affect wildtype HTT protein levels in either patient-derived or healthy donor cell lines

### **Off-Target Analysis Reveals Specificity of LETI-101**





No off-target editing observed at sequenced sites & no off-target liabilities identified



- Intrastriatal injections of LETI-101 in BACHD mice at six ascending doses (cohorts A-F)
- 3-month in-life duration → striatal bulk tissue analyzed


Dose-dependent AAV vector copy, guide RNA expression, & LEG-B expression

**!!**..|

life edit

an **elevate**bia company

### LETI-101 Dose-Dependent Expression & Activity in Striatum of BACHD Transgenic Rodent Model




- Intrastriatal injections of LETI-101 in BACHD mice at six ascending doses (cohorts A-F)
- 3-month in-life duration  $\rightarrow$  bulk striatal tissue harvested and analyzed

|'|,|

life edit

an **elevate**bia company

### **Overview of Combination Product LETI-101+neuroinfuse™** intraparenchymal drug delivery system (Renishaw)



- Reflux inhibiting feature facilitating convection enhanced delivery forms a pressure gradient at tip of infusion catheter to deliver drug product directly through the interstitial space
- Implantation of catheters and infusion can be performed outside MRI; all infusions can be performed simultaneously reducing procedure time




LETI-101 can be safely administered quickly while patient is awake, reducing exposure to

l'**'**ı.l

## One Month Tolerability and Biodistribution of LETI-101 in Adult Cynomolgus Monkeys






Group	Subjects	Treatment	Dose (vg/brain)	Volume per Hemisphere (µL)
Vehicle	1M	Vehicle	0	Caudate: 75, Putamen: 150
Low Dose	1M / 1F	LETI-101	Low Dose	Caudate: 75, Putamen: 150
High Dose	1M / 2F	LETI-101	High Dose	Caudate: 75, Putamen: 150



© 2023

- Administration performed using the Renishaw Acute Drug Delivery system with Neuroinfuse™ catheters
- No LEG-B PAM in NHP HTT exon 50 homologous region

### LETI-101 Dose-Dependent Biodistribution in HD Critical Brain Regions of Cynomolgus Macaque






- Intrastriatal injections of LETI-101 in Cynomolgus monkeys at 2 dose levels
- X-axis denotes tissue punch #
- 1-month in-life duration
- Data represent mean ± SD
  - Intrastriatal delivery of LETI-101 in cynomolgus macaques was well-tolerated; all animals survived to scheduled necropsy with no noted untoward clinical observations
  - Dose-dependent vector biodistribution, guide RNA expression, & LEG-B expression in the striatum was observed 1month following bilateral intrastriatal CED administration
  - NOAEL obtained for highest dose level evaluated

life edit

an **elevate**bia company

# One Month Tolerability and Biodistribution of LETI-101 in Adult Cynomolgus Monkeys





life edit an elevatebia company No change in immune response to LEG-B nuclease observed in serum or CSF following bilateral intrastriatal administration of LETI-101

### **LETI-101 Summary**



- 1. Delivery with a single AAV vector
- 2. Allele specific targeting of *mHTT*
- 3. Efficient delivery to CNS when delivered via AAV5
- 4. Clinically relevant reduction of mHTT protein in BACHD transgenic mice
- 5. Dose-dependent biodistribution and transgene expression across brain regions that are critically vulnerable in HD in NHPs

### Life Edit Therapeutics met with MHRA in September 2024 to review LETI-101 program

Preclinical data package well received; deemed "sufficient and comprehensive" including off-target characterization strategy



> Concurrence with overall clinical trial design and CMC strategy



### End

